Submission declined on 10 October 2024 by AlphaBetaGamma (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Once you save your changes using the "Publish changes" button below, you will be able to resubmit your draft for review by pressing the "Resubmit" button that will appear here. |
Submission declined on 27 April 2024 by ToadetteEdit (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by ToadetteEdit 6 months ago. |
Submission declined on 19 July 2023 by Tutwakhamoe (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by Tutwakhamoe 15 months ago. |
Submission declined on 7 March 2023 by Tails Wx (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. Declined by Tails Wx 19 months ago. |
Submission declined on 10 November 2022 by 97198 (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by 97198 23 months ago. |
Stanley T Crooke | |
---|---|
Born | March 28, 1945 |
Education | MD - Baylor College of Medicine, Houston, TX, 1974
PhD Pharmacology - Baylor College of Medicine, Houston, TX, 1971 BS Pharmacy - Butler University, Indianapolis, IN, 1966 |
Stanley T. Crooke is an American pharmacologist and the founding CEO of Ionis Pharmaceuticals, an RNA-targeted therapeutics company. In 1989, he opened Isis Pharmaceuticals, now known as Ionis, which would go on to pioneer a drug discovery platform, antisense oligonucleotides[1]. Over the years, Ionis has developed several drugs including Spinraza[2], which is designed to treat spinal muscular atrophy (SMA). In 2020, Crooke founded the N-Lorem foundation, a non-profit designed to take advantage of the technology discovered at Ionis to provide experimental treatment to patients with extremely rare genetic disorders.